Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases by Baratti, D. et al.
Editorial
Past, present and future of adjuvant HIPEC in patients at high risk for
colorectal peritoneal metastases
Peritoneal metastases (PM) from colorectal cancer (CRC) still
represent a huge health-care problem. Recent population-based
studies report an overall 3.5e4.2% incidence of CRC-PM after poten-
tially curative primary surgery [1,2]. These rates can reach up to
about 25% in locally advanced CRC penetrating visceral peritoneum
(pT4a), or directly infiltrating surrounding organs (pT4b) [1e3].
Accordingly, the peritoneum is one of the most common site of
metastatic spread for CRC, following the liver and lung, even
though incidences may be likely underestimated because PM are
more difficult to detect than liver or lung metastases.
A strategy involving local-regionally delivered chemotherapy to
prevent the outgrowth of occult peritoneal seeding intomacroscopic
metastases is supported by a strong rationale: first, cytoreductve sur-
gery (CRS) combined with hyperthermic intraperitoneal chemo-
theray (HIPEC) improve CRC-PM survival, but most patients are not
suitable for this demanding treatment due to extensive peritoneal
involvement, systemic metastases, and/or poor clinical conditions.
Second, CRS/HIPEC is maximally effective and safe when small-
volume disease is treated. Third, in the palliative setting,modern sys-
temic chemotherapy (s-CT) and targeted agents appear to be less
effective for peritoneal metastatic CRC than non-peritoneal metasta-
tic CRC. Finally, the absence of symptoms, as well as current limita-
tions of imaging, hamper early diagnosis and treatment [3].
On these bases, the use of HIPEC for the prevention or early
treatment of CRC-PM has been tested at different time-points,
either simultaneously with primary surgery [3e5], at the time of
second-look surgery after adjuvant s-CT [6], or as a staged proced-
ure at 5e8 weeks postoperatively [7]. Since we were amongst the
first groups to investigate the role of adjuvant HIPEC, we were sur-
prised to read that in the COLOPEC randomized trial such a treat-
ment approach failed to demonstrate improved peritoneal-free
survival in pT4a/b or perforated CRC [7].
The Dutch investigators randomly assigned patients to
oxaliplatin-based HIPEC given either at primary resection in 9% of
patient, or 5e8 weeks later in the remaining 91%, and followed
by adjuvant s-CT. Patients assigned to the control arm received
standard adjuvant s-CT only. All patients showing no recurrent dis-
ease at 18 months underwent diagnostic laparoscopy. There was no
difference in 18-month peritoneal-free survival between groups:
80.9% (95% confidence interval [CI] 73.3e88.5) for the experimental
arm vs. 76.2% (95%CI 68e84.4) for the control arms (log-rank two-
sided P ¼ 0.28) [7]. Analogously, the randomized French trial Pro-
phylochip failed to demonstrate a survival benefit associated with
a strategy of systematic second-look surgery plus HIPEC in high
risk patients, as compared with standard surveillance. The French
trial was done in a different clinical setting than the COLOPEC trial,
as high risk to develop CRC-PMwas defined as history of ovarian or
low-volume peritoneal metastases resected with the primary, or
perforated primary tumor [6].
Investigators in Rome and Milan have completed two pilot
studies to test oxaliplatin-based HIPEC, and mitomycin plus
cisplatin-based HIPEC, respectively. In both studies, HIPEC was
given at the same time as primary resection [3,4]. Limiting the anal-
ysis to patients with pT4a/b or perforated CRC (the same population
as in COLOPEC trial), PM occurred in one of sevenpatients treated in
Rome, with a median follow-up of 48months [4]. After an up-dated
follow-up of more than 10 years (median 128.0 months), PM has
occurred so far in one of 14 patients treated in Milan, and another
patient has died of liver metastases (Baratti D, unpublished data).
The study by Tentes et al. is the third relevant literature series of
simultaneous adjuvant HIPEC. The authors report no PM occurring
in 15 patients treated with either oxaliplatin or mitomycin, with a
median follow-up of 17 months [5].
Putting together these three series of adjuvant HIPEC delivered
at primary resection, PM occurred in 2 of 36 patients (5.6%) [3e5].
This figure compares favourably with the peritoneal failure rate of
19% following staged adjuvant HIPEC in the experimental arm of
the COLOPEC trial, and also the 23% rate in control arm [7].
Although it may be not scientifically sound to compare outcome re-
sults across different trials, it has to be taken into consideration that
patients were included in both COLOPEC trial and the aforemen-
tioned series essentially on the base of pT4 primary stage, with
minimal likelihood that a selection bias could have occurred. In
this aspect, the adjuvant setting is different from the setting of clin-
ically manifest PM, where multiple variables, such as peritoneal
disease extent and distribution, response to previous therapies,
and patient conditions, may influence appropriate physician judg-
ment in the selection of such therapies outside the context of a ran-
domized controlled trial.
The simultaneous time setting for adjuvant HIPEC is further sup-
ported by a pharmacological rationale (i.e. better exposure to anti-
blastic agents before viable tumor cells are entrapped in
postoperative adhesions) [3]. Also, it is worth to note that 9% of pa-
tients in COLOPEC trial were found with PM at surgical exploration
preceding intentional adjuvant HIPEC, and these patients could
have been potentially cured by HIPEC at primary surgery [7].
Finally, bilateral adnexectomy and greater omentectomy were
routinely performed in Milan and Rome series [3,4]. These proced-
ures may have contributed to improved peritoneal control by
ensuring better drug circulation throughout the abdominal cavity,
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and removing target organs of peritoneal dissemination.
Drawbacks of the simultaneous setting are logistic issues, difficult
preoperative/intraoperative identificationofT4 tumors, andpotential
toxicity of HIPEC. However, three independent studies have demon-
strated that in an appropriate environment simultaneous adjuvant
HIPEC is feasible [3e5].Regardingsafety issues,fiveanastomotic leaks
(5.7%) and three HIPEC-related toxicities, namely two transient grade
3 renal failures, and one grade 2 pancreatitis (3.4%), were observed in
the total of 87 patients from the three series of simultaneous HIPEC,
that included also pT3 primaries and completely resected ovarian or
low-volume peritoneal metastases.
This incidence of anastomotic leaks may be slightly higher than
common elective colorectal surgery, but this has to be seen not only
in light of the potentially adverse impact of HIPEC on anastomotic
healing, but also of the more extensive surgery performed in pa-
tients with more advanced disease. Such a complication rate ap-
pears to be compatible with the potential benefit, and even the
risk of overtreatment for those patients inwhich a locally advanced
primary stage should be erroneously diagnosed by preoperative
studies, analogously to preoperative radiation in rectal cancer.
Oxaliplatin efficacy have become matter of intense debate after
the negative results of COLOPEC and Prophylochip trials in the adju-
vant setting, and Prodige-7 trial in patients with clinically manifest
CRC-PM [8]. Although oxaliplatin is one of the drugs of choice for
metastatic CRC, factors such as insufficient exposure time (30 min-
ute), adverse effects of carrier solution (Dextrose 5%), and potential
drawbacks of hyperthermia have been related to the lack of survival
benefit [8]. Patients undergoing simultaneous adjuvant HIPEC were
treated according to different protocols (open vs. close-abdomen
technique, mitomycin with or without cisplatin vs. oxaliplatin,
isotonic vs. hypotonic carrier solution, 30 vs. 60 vs. 90 minute
perfusion time), thus precluding anymeaningful comparison [3e5].
In conclusion, we believe that future trials of adjuvant HIPEC
should not be discouraged. Besides oxaliplatin efficacy issues,
future trial design must address the question whether staged vs.
simultaneous adjuvant HIPEC, and prophylactic resection of target
organs may impact outcomes.
Accordingly, the PROMENADE (NCT02974556) trial is open in
seven Italian high-volume centers. Patients with cT3c/d CRC (depth
of invasion beyond the outer border of the muscularis propria
>5e15 mm, and >15 mm, respectively), and cT4a/b CRC (any N,
M0), selected by multidetector computed tomography (MDCT)
will be randomized between standard surgery vs. proactive surgical
management. The latter includes greater omentectomy, appendec-
tomy, resection of the liver round ligament and bilateral adnexec-
tomy in post-menopausal women, plus oxaliplatin-based
simultaneous adjuvant HIPEC. The choice to include cT3c/d CRC is
not only based on the accuracy of MDCT to discriminate between
pT1-2 and pT3-4 tumors, but also to correctly identify pT3c or
more advanced disease [9]. On the other hand, differentiating be-
tween pT3 and pT4 tumors on imaging still remains challenging.
Furthermore, pT3 tumors invading the peritoneal elastic lamina
(30% of the cases) have a prognosis that approximates those of
pT4 cancers [10]. Ninety-seven patients will be enrolled in each
arm. In both groups, postoperative adjuvant s-CT will be given.
The primary study endpoint is the incidence of peritoneal recur-
rence at 36 months from randomization.
A Spanish collaborative study with a similar design (HIPECT4,
NCT02614534) is actively enrolling patients with cT4a/b CRC to
test mitomycin-based adjuvant HIPEC plus resection of target or-
gans at primary surgery.
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